As US markets plunged, these 2 stocks hit all-time highs

Some companies can stand up to tough conditions on Wall Street.

| More on:
a young girl has a wide eyed look with pursed lips as though saying 'ooh' as if receiving interesting news or a juicy piece of gossip.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Investors lost confidence in the stock market on Tuesday, responding negatively to inflation readings for August that were higher than most had expected. By the end of the day, the Dow Jones Industrial Average (DJINDICES: ^DJI) had registered one of its largest daily point drops in its history, and the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) were down even more sharply on a percentage basis.

IndexDaily Percentage ChangeDaily Point Change
Dow(3.94%)(1,276)
S&P 500(4.32%)(178)
Nasdaq(5.16%)(633)

Data source: Yahoo! Finance.

All 30 Dow stocks were down, and just five stocks out of the S&P 500 managed to eke out gains on the day. Yet there were a couple of companies whose shares not only managed to move higher but also set new all-time highs. Below, you'll learn more about why Albemarle Corporation (NYSE: ALB) and Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) bucked the big downward move on Wall Street and moved further into record territory.

Albemarle keeps charging up

Albemarle ended the day up just a fraction of a percent after having climbed as much as 3.5% above its closing level on Monday. Fundamentally, though, the specialty chemical company continued to benefit from high demand for some of its most important material products.

Historically, Albemarle has played a key role in the energy and industrial sectors. Its bromine-related products are used in applications ranging from oilfield drilling to food safety and water treatment. Its catalysts business helps refining and petrochemical companies process heavy oil and produce cleaner fuels, while also serving customers in the electronics and pharmaceutical markets.

Lately, though, investors know Albemarle best for its exposure to the lithium market. In the second quarter of 2022, Albemarle saw revenue nearly double from year-ago levels, with earnings coming close to quadrupling year over year. Although strong conditions in the bromine business provided a boost, lithium was the biggest factor, driven by high demand from the electric vehicle sector.

The trend toward EV adoption looks like it'll take years to play out, and as long as battery technology relies on lithium, Albemarle can expect demand to remain high. That should play to Albemarle's strengths and keep shares strong over the long run.

A big winner for Catalyst

Catalyst Pharmaceuticals climbed about 1% on Tuesday, although it had been up more than 13% earlier in the day. The company's primary treatment has done well, and Catalyst got a vote of confidence from index managers at S&P Dow Jones Indices.

Catalyst's stock has been on the rise as sales of its Firdapse drug for treating the rare disease Lambert-Eaton myasthenic syndrome have climbed sharply. That has put Catalyst in the enviable position of having positive cash flow, which is a rare thing for a small biopharmaceutical company and makes it possible for the company to fund development of new pipeline treatments without resorting to expensive capital-raising activities.

S&P Dow Jones Indices announced late Monday that Catalyst would become a member of the S&P SmallCap 600 index effective before the market opens on Thursday, Sept. 15. The company replaces ManTech International, which is set to go private in an acquisition that should close in the near future.

Becoming a part of a stock index doesn't have any impact on Catalyst's fundamental business, but it does raise awareness of the drugmaker and its prospects for further growth. Shareholders now hope that Catalyst can keep executing well and make the most of its opportunity in Firdapse while also adding more approved drugs to its product lineup in the years to come.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

A young entrepreneur boy catching money at his desk, indicating growth in the ASX share price or dividends
International Stock News

Why this high-flying investor is selling Tesla shares and buying this US tech stock instead

Ark Invest funds have been selling the electric vehicle maker's stock over the last few weeks and reinvesting the proceeds…

Read more »

two computer geeks sit across from each other with their laptop computers touching as they look confused and confounded by what they are seeing on their screens.
International Stock News

Is Nvidia stock heading to $175?

The bulls are lining up ahead of Nvidia's earnings report next week.

Read more »

A woman holds a bitcoin token in her hand as she smiles at the camera in the background.
International Stock News

Bitcoin keeps soaring. Could it hit $95,000 this week?

Could the current crypto rally have enough juice to push the coin above that once-inconceivable level?

Read more »

A boy in a green shirt holds up his hands in front of a screen full of question marks.
International Stock News

2 reasons to buy Nvidia shares before November 20 (and 1 reason to wait)

This top AI stock has soared nearly 200% this year!

Read more »

A group of friends push their van up the road on an Australian road.
International Stock News

Why Tesla stock just pulled back

Tesla finally hit a speed bump after a blistering post-election rally.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
International Stock News

Why Tesla stock keeps going up

Tesla stock costs more than $1 trillion now. Is that too expensive?

Read more »

A businessman in soft-focus holds two fingers in the air in the foreground of the shot as he stands smiling in the background against a clear sky.
International Stock News

2 Numbers I'll be looking for on November 20 when Nvidia reports earnings

While many analysts and investors will be looking at revenue and profit growth, two other figures are more important to…

Read more »

A man wearing a blue jumper and a hat looks at his laptop with a distressed and fearful look on his face.
International Stock News

Magnificent Seven: Unstoppable tech stock giants or risky buys?

Did you know the "Magnificent Seven" moniker was meant as a warning, not an endorsement? Check out the risks and…

Read more »